

**Northern, Eastern and Western Devon Clinical Commissioning Group  
South Devon and Torbay Clinical Commissioning Group**

**Stage 1 Rapid Equality Impact Assessment Form –see checklist**

**Please use the guidance provided and give particular consideration to the needs of people with protected characteristics age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, sex, race, religion or belief and sexual orientation.**

This Equality Impact Assessment is applicable to the populations of Northern, Eastern and Western Devon Clinical Commissioning Group and South Devon & Torbay Clinical Commissioning Group who work together to carry out their responsibilities for making local decisions about the funding of medicines and treatments in the NHS.

Title of work:  <b>Commissioning policy: Fidaxomicin (Dificlir®) for the treatment of adults with <i>Clostridium difficile</i> Infection (CDI)</b>
----------------------------------------------------------------------------------------------------------------------------------------------------------

Who does the proposed piece of work affect?			
Staff	Patients	Carers	Public
<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

1. What are the aims and objectives of the work being assessed?  To establish a commissioning position on the use of Fidaxomicin for the treatment of adults with <i>Clostridium difficile</i> Infection (CDI), also known as <i>C. difficile</i> -associated diarrhoea (CDAD).  Clinicians with an interest in, and patients with severe or recurrent disease should have clarity on how Fidaxomicin will be commissioned by the Clinical Commissioning Groups in Devon.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

		Yes	No
2.	Will the proposal have any impact on discrimination, equality of opportunity or relations between groups?		✓
3.	Is the proposal controversial in any way (including media, academic, voluntary or sector specific interest) about the proposed work?		✓
4.	Will there be a positive benefit to the users or workforce as a result of the proposed work?	✓	
5.	Will the users or workforce be disadvantaged as a result of the proposed work?		✓
6.	Is there doubt about answers to any of the above questions (e.g. there is not enough information to draw a conclusion)?		✓

**If the answer to any of the above questions is yes (except for question 4) or you are unsure of your answers to any of the above you should complete a full impact assessment.**

A Full Impact Assessment is required  is not required

**If a full impact assessment is not required briefly explain why and provide evidence for the decision.**

This policy clarifies the commissioning position that the routine commissioning fidaxomicin is **not** accepted in Devon for the treatment of adults with *Clostridium difficile* infections (CDI) also known as *C. difficile*-associated diarrhoea (CDAD).

**Job Title:** Clinical Effectiveness Governance Manager

**Directorate:** Clinical Effectiveness and Medicines Optimisation

**Date of assessment:** 19<sup>th</sup> August 2014

For your records, keep one copy of this rapid impact assessment form and send an electronic copy, with the Board paper for publishing.